Real-World Comparative Effectiveness Research and Related Economic Outcomes Among Nonvalvular Atrial Fibrillation Patients Using Oral Anti-coagulants
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 14 Nov 2018
At a glance
- Drugs Apixaban (Primary) ; Dabigatran etexilate (Primary) ; Rivaroxaban (Primary) ; Warfarin (Primary)
- Indications Embolism
- Focus Adverse reactions
- Acronyms ARISTOPHANES
- Sponsors Bristol-Myers Squibb
- 14 Nov 2018 Results of a sub-group analysis presented at the 91st Annual Scientific Sessions of the American Heart Association.
- 14 Nov 2018 Results from a sub-group analysis presented at the 91st Annual Scientific Sessions of the American Heart Association
- 11 Nov 2018 According to a Bristol-Myers Squibb media release, real-world evidence (RWE) from a sub-analysis of this trial was presented at the American Heart Association Scientific Sessions 2018.